STADA success driven by Specialty segment growth
German drugmaker STADA Arzneimittel (SAZ: Xetra) has reported record earnings on revenues growth in its financial first quarter.
Group adjusted, constant-currency (cc) revenues rose by 4% on an organic basis to 1.08 billion euros ($1.23 billion). This growth was driven by a double-digit increase in revenues in the group’s Specialty segment, aided by further market penetration with the Uzpruvo (ustekinumab) biosimilar launched in Europe from July 2024.
Adjusted cc earnings before interest, tax, depreciation and amortization (EBITDA) jumped by 5% to 245 million euros, a historic high against a strong prior-year base.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze